在收购 Spyre 之前,Aeg...查看全文
美股滚雪球2023-06-25 15:05
$Aeglea生物制药(AGLE)$ 宣布以换股交易的方式收购Spyre Therapeucs。通过收购,Aeglea(AGLE)获得了SPY001和SPY002,这两种炎症性肠病候选抗体预计将于2024年进入临床。
Aeglea(AGLE)还就PIPE投资达成协议,筹集2.1亿美元,其中投资者将获得721452股a系列优先股(721452000股,转换为普通...查看全文
产业链观察2022-08-19 20:19
药闻▶2022年8月18日,临床阶段的生物技术公司$Aeglea生物制药(AGLE)$今天宣布,用于治疗精氨酸酶1缺陷(ARG1-D)的pegzilarginase市场授权申请(MAA)已经提交给欧洲药品管理局(EMA)并成功通过验证。该MAA是由Aeglea在欧洲和中东的商业化合作伙伴Imedica Pharma AB提交的。
Pe...查看全文
Aeglea生物制药(AGLE)2022-08-04 18:13
$Aeglea生物制药(AGLE)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001564590-22-027895 Act: 34 Size: 9 MB 网页链接查看全文
Aeglea生物制药(AGLE)2023-11-28 05:35
$Aeglea生物制药(AGLE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-066131 Size: 9 KB 网页链接查看全文
Aeglea生物制药(AGLE)2023-11-28 05:35
$Aeglea生物制药(AGLE)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000950170-23-066141 Size: 12 KB 网页链接查看全文
Aeglea生物制药(AGLE)2023-11-28 05:35
$Aeglea生物制药(AGLE)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000950170-23-066136 Size: 10 KB 网页链接查看全文
Aeglea生物制药(AGLE)2023-11-24 19:05
$Aeglea生物制药(AGLE)$ 8-K Current report, items 5.03, 5.07, 7.01, and 9.01 Accession Number: 0001193125-23-282424 Act: 34 Size: 179 KB 网页链接查看全文
Aeglea生物制药(AGLE)2023-11-28 05:45
$Aeglea生物制药(AGLE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-066146 Size: 5 KB 网页链接查看全文
Aeglea生物制药(AGLE)2023-11-28 05:35
$Aeglea生物制药(AGLE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-066143 Size: 5 KB 网页链接查看全文
$Aeglea生物制药(AGLE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-066146 Size: 5 KB 网页链接
$Aeglea生物制药(AGLE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-066131 Size: 9 KB 网页链接
$Aeglea生物制药(AGLE)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000950170-23-066136 Size: 10 KB 网页链接
$Aeglea生物制药(AGLE)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000950170-23-066141 Size: 12 KB 网页链接
$Aeglea生物制药(AGLE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-066143 Size: 5 KB 网页链接
$Aeglea生物制药(AGLE)$ 8-K Current report, items 5.03, 5.07, 7.01, and 9.01 Accession Number: 0001193125-23-282424 Act: 34 Size: 179 KB 网页链接
$Aeglea生物制药(AGLE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-003387 Act: 33 Size: 1 KB 网页链接
$Aeglea生物制药(AGLE)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001193125-23-277992 Act: 33 Size: 6 MB 网页链接
$Aeglea生物制药(AGLE)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-23-277985 Act: 34 Size: 798 KB 网页链接
$Aeglea生物制药(AGLE)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001683168-23-008109 Act: 34 Size: 46 KB 网页链接